Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice
Takuya Kobayashi, … , Toru Kita, Shuh Narumiya
Takuya Kobayashi, … , Toru Kita, Shuh Narumiya
Published September 15, 2004
Citation Information: J Clin Invest. 2004;114(6):784-794. https://doi.org/10.1172/JCI21446.
View: Text | PDF
Article Cardiology

Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice

  • Text
  • PDF
Abstract

Production of thromboxane (TX) A2 and PG I2/prostacyclin (PGI2) is increased in patients with atherosclerosis. However, their roles in atherogenesis have not been critically defined. To examine this issue, we cross-bred atherosclerosis-prone apoE-deficient mice with mice deficient in either the TXA receptor (TP) or the PGI receptor (IP). Although they showed levels of serum cholesterol and triglyceride similar to those of apoE-deficient mice, apoE–/–TP–/– mice exhibited a significant delay in atherogenesis, and apoE–/–IP–/– mice exhibited a significant acceleration in atherogenesis compared with mice deficient in apoE alone. The plaques in apoE–/–IP–/– mice showed partial endothelial disruption and exhibited enhanced expression of ICAM-1 and decreased expression of platelet endothelial cell adhesion molecule 1 (PECAM-1) in the overlying endothelial cells compared with those of apoE–/–TP–/– mice. Platelet activation with thrombin ex vivo revealed higher and lower sensitivity for surface P-selectin expression in platelets of apoE–/–IP–/– and apoE–/–TP–/– mice, respectively, than in those of apoE–/– mice. Intravital microscopy of the common carotid artery revealed a significantly greater number of leukocytes rolling on the vessel walls in apoE–/–IP–/– mice than in either apoE–/–TP–/– or apoE–/– mice. We conclude that TXA2 promotes and PGI2 prevents the initiation and progression of atherogenesis through control of platelet activation and leukocyte-endothelial cell interaction.

Authors

Takuya Kobayashi, Yoshio Tahara, Mayumi Matsumoto, Masako Iguchi, Hideto Sano, Toshinori Murayama, Hidenori Arai, Hiroji Oida, Takami Yurugi-Kobayashi, Jun K. Yamashita, Hiroyuki Katagiri, Masataka Majima, Masayuki Yokode, Toru Kita, Shuh Narumiya

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Generation and atherosclerotic lesions of apoE_/_TP_/_ and apoE_/_IP_/_ ...
Generation and atherosclerotic lesions of apoE_/_TP_/_ and apoE_/_IP_/_ mice. (A) Strategy for PCR analysis of WT and targeted alleles of TP and IP. Primers are shown by arrowheads. Amplified fragments are shown by broken lines. Neo, neomycin-resistance gene. (B) Representative PCR for TP and IP alleles of apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice. (C) Representative oil red O staining of aortic sinus sections of apoE_/_ (middle), apoE_/_TP_/_ (lower), and apoE_/_IP_/_ (upper) mice. Scale bar: 200 μm. (D) Time course of atherosclerotic lesion development in apoE_/_ (open circles), apoE_/_TP_/_ (filled circles), and apoE_/_IP_/_ (filled squares) mice. Data are means ± SEM (n = 10 for 15-week-old apoE_/_ and apoE_/_IP_/_ and 20-week-old apoE_/_ and apoE_/_TP_/_ male mice; n = 6 for 15-week-old apoE_/_TP_/_, 20-week-old apoE_/_IP_/_, and 30-week-old apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice). *P < 0.05 and **P < 0.01 versus apoE_/_ mice. (E) Representative Sudan IV staining of en face preparations of aortas from apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice at 20 weeks of age. Scale bars: 2 mm. (F) Quantification of en face atherosclerotic lesions in apoE_/_, apoE_/_TP_/_ and apoE_/_IP_/_ mice at 20 weeks of age. Data are means ± SEM (n = 5 each). *P < 0.05 and **P < 0.01 for bracketed comparisons. (G) Representative hematoxylin and eosin staining of innominate artery sections of apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice at 45 weeks of age. Scale bar: 20 μm. (H) Quantitative analysis of innominate atherosclerotic areas in apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice at 45 weeks of age. Data are means ± SEM (n = 10 each). *P < 0.05 and **P < 0.01 for bracketed comparisons.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts